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Abstract 
Distance-based supervised pattern recognition method (PRM) – 
discriminant analysis (DA) in principal component (PC) space described by 
Mahalanobis distance (MD) - was suggested for definition of batch-to-batch 
dispersion of 22 drugs, produced by 14 manufacturers. The range of under 
test medicines numbered 18 pharmacological classes, including biologics, 
microbiological drugs and combined drugs, containing several active 
ingredients. Thermo Scientific ANTARIS II FT-NIR Analyzer collected 
spectra in diffuse reflectance mode, data pre-processing and analysis were 
performed using the TQ Analyst software. The value of spectral dispersion 
for the most samples in the research except capsules did not exceed 10 MD, 
what correlated with the values met in literature (Mark & Tunnell, 1985). 
Mahalanobis distance threshold, which was calculated in leave-one-out-cross 
validation (LOOCV), proved equal 3 for the majority of drugs, what was in a 
good agreement with the theoretically determined limit (Mark, 2001, p. 321). 
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Introduction 
Since near infrared spectroscopy has been introduced as a general 
analytical method in the official pharmacopoeias of Europe and the United 
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States, it becomes a frequently used technique within pharmaceutical 
industry and drug quality control system (European Pharmacopoeia, 2011; 
The United States Pharmacopoeia, 2011). Together with multivariate 
statistics, NIR spectroscopy is used in a broad range of applications for 
precise material characterization: identification of active pharmaceutical 
ingredients (API), raw materials, products authentication, homogeneity 
analysis, control of polymorphs, optical isomers and counterfeit products 
screening (Blanco & Romero, 2001; Frasson Scafi & Pasquini, 2001; Plugge 
& van der Vlies, 1996; Rodionova & Pomerantsev, 2010; Sarraguc & Lopes, 
2009). As for quantitative analysis, examples include the determination of 
physical parameters, water content and dose uniformity (Elizarova et al., 
2011; Reich, 2005). More than that, NIR technique, due to its possibilities of 
direct and fast measurements, is actively implemented to the manufacturing 
application in concept of process analytical technology (Ritchie et al., 2003; 
Mӓrk et al., 2010). Variety of NIRS utilization indicates the techniques 
obvious advantages, however still considerable attention should be paid to 
the existence of certain methodological difficulties (Blanco et al., 1998; 
Blanco & Alcala, 2005). In the framework of this research, those dealt 
mainly with the qualitative analysis and drug authentication are considered. 
A proved matter is that drug identification from the mere visual 
inspection of its NIR spectrum requires much effort; rather, a pattern 
recognition method must be applied to a library of spectra for this purpose. 
An ideal pattern recognition method should be simple to use, easily 
understood by non-mathematician, should correctly identify unknown and 
reject unacceptable samples (Gemperline & Boyer, 1995). Supervised 
modeling methods are of a best choice for sample qualifying procedure, 
because they rely on some prior training of the system with objects known to 
belong to the determining class. Such methods can be of the discriminant or 
modeling types. 
Discriminant methods split the pattern space into as many regions as 
the classes encompassed by the training set and establish bounds that are 
shared by the spaces. Discriminant analysis is one of the most common 
discriminant methods, allows attributing an unknown sample to a certain 
class, what is especially appreciable in pharmaceutical quality control. The 
bounds, established during the analysis, can be based on correlation 
coefficients and distances. 
Distance-based methods possess a superior discriminating power and 
allow highly similar compounds (e.g. several production batches of one 
drug) to be distinguished (Blanco & Alcala, 2005). The most commonly used 
distance measures are the Euclidean distance (ED) and the Mahalanobis 
distance. Both distances can be calculated in the original variable space and 
in the principal component (PC) space. The ED is easy to compute and 
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interpret, but this is less the case for the MD (De Maesschalck et al., 2000). 
The discussion of the pros and cons of using ED or MD in the field of 
multivariate calibration is outside the scope of this paper (Brereton, 2007; De 
Maesschalck et al., 2000; Mark, 2001, p. 310). However, a review of number 
on-topic scientific papers demonstrated successful experience of 
Mahalanobis distance use in PRM techniques for pharmaceuticals 
classification (Andre, 2003; Gemperline & Boyer, 1995; Mӓrk et al., 2010; 
Mark & Tunnell, 1985; Plugge & van der Vlies, 1996; Sarraguc & Lopes, 
2009; Ritchie et al., 2003; Whitfield et al., 1987). Already in 1985 it was 
proposed: “Using MD for classification allows computer programs to be 
written that contain a large measure of protection against marginal 
conditions, in a form that is easily understood and evaluated by the non-
mathematician” (Mark & Tunnell, 1985). Taking into account all of the 
above, near-IR spectroscopy together with DA and MD appears to be a good 
instrument for drug authentication. It is just as well, but for any quality 
control laboratory there arises a question - what distance (MD) is considered 
a threshold for the class of authentic drugs? There is no one certain answer. 
Most of the revised articles discussed the problem of proper MD control 
limits determination, as well as reported similar results and conclusions. The 
earliest paper suggested that MD represented a measure of standard 
deviation, therefore the theoretically boundary of a group was thought to be 
three standard deviations away from the groupmean (Mark & Tunnell, 1985). 
Nevertheless, the authors’ practical experience indicated, that a more 
reasonable cutoff point due to the presence of variations in the size, shape, or 
orientation between the different groups, small changes in the physical 
nature of the samples, small drifts in the instrument, etc. lied at Mahalanobis 
distance between 10 and 15 (Mark & Tunnell, 1985). Whitefield et al. (1987) 
also considered a MD criterion of 3 for deciding whether the sample belongs 
to the specified population unjustifiably restrictive. They calculated 
theoretical values for confidence limits for MD, depending on the sample 
size and number of wavelengths used. Ritchie et al. (2003) showed, the 
values from the Whitefield’s tables were in good agreement with the 
empirical MD values, obtained for all their calibration samples. According to 
their results, based on combined criteria, the threshold for MD was set at 4. 
At last, Mӓrk et al. (2010) said, the confidence limit for quality control, 
depending on the definition of the model number degrees of freedom had to 
be set empirically, based on an extensive testing effort. 
That is why our research is focused on the issue of determination the 
qualification thresholds for the classes of authentic medicines and their 
comparison with the theoretical and experimental limits. In a certain way 
drugs are produced with some tolerance in API concentration, possible 
variations in excipients, impurities, moisture, density, viscosity or particle 
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size, while their NIR spectra reflect the whole quality of the drug and any 
deviations in the manufacturing process (Rodionova & Pomerantsev, 2010; 
Blanco & Alcala, 2005). Therefore, it can be proposed to use the meaning of 
acceptable dispersion between production batches, expressed in MD, as the 
MD quality thresholds for identical drugs. In other words, the objective of 
this paper is to assess the batch-to-batch dispersion of 22 different 
pharmaceuticals using NIR reflectance spectroscopy technique and highly 
accurate, easy understandable supervised pattern recognition method, 
provided by commercially available software.  
Test samples 
Table 1 presents the test sample set. Pharmaceuticals for the research 
were selected from the archival samples of the quality control laboratory, 
involved in the procedure of drug quality declaration. The choice of samples 
in the archive was in line with the presence of the highest number of series 
(at least 6), manufactured nearly at one period of time. The medicines quality 
was preliminary guaranteed by successful passing of conventional tests: 
description, packing, labeling, identification, assay, purity, disintegration 
test, average tablet weight, uniformity of content. Analysis of each drug was 
held in accordance with the regulatory requirements using different chemical 
and physicochemical methods: identification reactions, thin-layer 
chromatography, HPLC, ultraviolet spectroscopy, titration analysis. All 
quality indexes fitted into the normative limits, proving the high level of 
samples quality. 
Table 1. Test set of pharmaceuticals 
№ 
SAMPL
E 
NAME, 
TYPE 
ACTIVE 
INGREDIEN
T 
DOSE, 
mg 
MAIN 
EXCIPIEN
T 
DOSAG
E 
FORM 
MANUFAC
-TURER 
COUNTRY 
BATCHE
S 
NUMBER
/TABLET
S 
(capsules) 
NUMBER 
SPEC-
TRA 
NUM-
BER 
1 A1 
original 
chondroitin 
sulfate 
500 talk capsules A/ France 16/48 144 
2 B1 
original 
pipemidic acid 200 magnesium 
stearate, 
silicon 
dioxide 
colloidal, 
corn starch 
capsules B/ Slovenia 25/75 225 
3 C1 
generic 
fluconazole 150 lactose 
monohydrat
e, starch, 
silicon 
dioxide 
colloidal 
anhydrous, 
capsules C/ 
Macedonia 
18/54 162 
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magnesium 
stearate 
4 C2 
generic 
clopidogrel 
hydrosulfate 
75 mannitol, 
MCC, 
silicon 
dioxide, talc, 
stearic acid 
film-
coated 
tablets 
C/ 
Macedonia 
10/30 90 
5 C3 
generic 
carvedilol 12,5 lactose, 
sucrose, 
povidone 
K25, 
methyl 
cellulose 
tablets C/ 
Macedonia 
26/78 234 
6 C4 
generic 
carvedilol 25 tablets C/ 
Macedonia 
26/78 234 
7 C5 
generic 
trimetazidine 
dihydrochlo-
ride 
35 hypromellos
e, MCC, 
silicon 
dioxide 
colloidal, 
magnesium 
stearate 
film-
coated 
tablets 
C/ 
Macedonia 
19/57 171 
8 C6 
generic 
amlodipine 
besylate 
10 lactose 
monohydrat
e, povidone, 
crospovidon
e, calcium 
stearate 
tablets C/ 
Macedonia 
36/108 324 
9 D1 
original 
dried powder 
of the bacteria 
strain Bacillus 
cereus IP 5832 
35 calcium 
carbonate, 
kaolin 
capsules D/ France 25/75 225 
10 E1 
generic 
diclofenac 
sodium 
200 lactose 
monohydrat
e, corn 
starch, 
povidone 
K30, sodium 
lauryl 
sulfate 
coated 
tablets 
E/ Serbia 8/24 72 
11 F1 
original 
amoxicillin, 
clavulanic 
acid 
875/ 
125 
Magnesium 
stearate, 
silicon 
dioxide 
colloidal 
coated 
tablets 
F/ UK 6/18 54 
12 G1 
generic 
bisacodyl 5 lactose 
monohydrat
e, wheat 
starch, 
silicon 
dioxide 
colloidal 
coated 
tablets 
G/ Bulgaria 6/18 54 
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anhydrous, 
talc 
13 G2 
original 
metamizol, 
pitofenon, 
fenpiverin 
500/ 
2/ 
0,02 
lactose 
monohydrat
e, wheat 
starch, talc, 
magnesium 
stearate 
tablets G/ Bulgaria 17/51 153 
14 H1 
generic 
ferrous sulfate, 
ascorbic acid 
360/ 
60 
magnesium 
stearate, 
povidone, 
polyethylene 
powder 
coated 
tablets 
H/ Sweden, 
UK 
6/18 54 
15 I1 
original 
chlorpyra-
mine 
hydrochlo-ride 
25 stearic acid, 
gelatin, 
sodium, talc, 
potato 
starch, 
lactose 
monohydrat
e 
tablets I/ Hungary 9/27 81 
16 J1 
original 
lornoxicam 4 calcium 
stearate, 
sodium 
bicarbonate, 
MCC, 
calcium 
phosphate 
coated 
tablets 
J/ Austria 7/21 63 
17 J2 
original 
lornoxicam 8 coated 
tablets 
J/ Austria 8/24 72 
18 J3 
original 
dry 
deproteinized 
derivative 
from calf 
blood 
200 magnesium 
stearate, 
povidone 
K90, talc, 
cellulose 
coated 
tablets 
J/ Austria 18/54 162 
19 K1 
original 
risperidone 2 lactose, corn 
starch, 
microcrystal
line 
cellulose, 
hypromellos
e, 
magnesium 
stearate, 
silicon 
dioxide 
colloidal 
anhydrous 
coated 
tablets 
K/ Italy 10/30 90 
20 L1 
original 
propyphena-
zone, 
paracetamol, 
caffeine, 
210/ 
250/ 
50/10 
magnesium 
stearate, 
sodium 
lauryl 
tablets L/ 
Macedonia 
23/69 207 
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codeine sulfate, 
silicon 
dioxide 
colloidal 
anhydrous, 
microcrystal
line 
cellulose 
21 M1 
original 
methyl-
prednisolone 
4 lactose 
monohydrat
e, corn 
starch, 
magnesium 
stearate, 
gelatin, talc, 
purified 
water 
tablets M/ Finland 19/57 171 
22 N1 
generic 
metamizol 500 magnesium 
stearate, 
polyethylene 
glycol 4000. 
tablets N/ India 30/90 270 
 
The manufacturer companies’ names and drug trade names were 
intentionally assigned the codes. In total the survey analyzed 22 products of 
13 European and one Indian manufacturer. The capital letter in the first 
column of table 1 indicated drugs’ appliance to the manufacturer. Most of 
the manufacturers were represented by one medicine, which was given the 
name like –“letter”1. Only three companies - C, G and J - were represented 
by several samples with the names like - “letter”1, “letter”2 etc. The first 
column of table 1 also specified which of the pharmaceutical samples were 
original and which were generic. In whole we analyzed 12 original and 10 
generic medicines. 
Among the test set there were drugs with the same API, but in 
different dose – sample C3 and C4 contained 12,5 and 25 mg of carvedilol; 
sample J1 and J2 – 4 and 8 mg of lornoxicam correspondingly. The most of 
the tested pharmaceuticals were coated, film-coated or uncoated tablets; only 
4 samples - A1, B1, C1 and D1 – were represented in encapsulated dosage 
form. 
As it follows from the Table 1, test samples (22 pharmaceuticals) had 
various chemical structures and belonged to 19 pharmacological classes 
including quinolones, probiotics, antiaggregants, beta-blockers, antianginals, 
calcium channel inhibitors, nonsteroidal anti-inflammatory drugs, antibiotics, 
laxatives, antihistamines, neuroleptics, glucocorticoids and others (see table 
1). The range of under test medicines included biologics, microbiological 
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drugs and combined drugs, containing several active ingredients (samples 
F1, G2, H1, L1). 
Table 1 also indicated the API dose, main drug excipients and the 
number of series, the number of tablets / capsules, the number of recorded 
spectra. 
NIR spectra acquisition 
The spectra were collected by Thermo Scientific ANTARIS II FT-
NIR Analyzer. All measurements were performed in diffuse reflectance 
operation mode using an integrating sphere module. Collecting the radiation 
from all dihedral angles, integrating sphere offered much higher 
reproducibility, minor spectral offset variability and less noise possibility 
caused by fiber optics 12. Each spectrum was the average of 16 scans 
performed in the spectral range of 4000-9000 cm-1at 4 cm-1 interval. An 
internal gold reference was used for automatic background collections, 
ensuring consistent sampling and repeatable results. To avoid the influence 
of blisters and glass bottles all samples were removed from their packaging. 
The tablets were measured by directly placing on the window surface of the 
integrating sphere; spectra were acquired from the both sides of the tablet, 
which was overturned before every measurement. The contents of capsules, 
emptied from opaque capsule shells, were put in a special glass cup with 
tight-fitting cap. To minimize scattering and reflection effects NIR spectra of 
capsules content were acquired after a standardized compaction procedure. 
Manufacturing variability was considered by including samples spectra from 
different production batches. NIR spectra were obtained 3 times per 
tablet/capsule for any 3 tablets/capsules from each batch, thus turned to 9 
spectra for each batch. Thereby the measurement procedure fully satisfied 
the demands of the European Medicines Agency (EMA), which indicated the 
formation of the spectral library using three or more NIR spectra for at least 
three batches of pharmaceutical 22. 
Data pre- processing 
To decrease the influence of various sources that are not related to the 
chemical or physical information carried by raw spectra we used usual pre-
processing technique, such as multivariate scatter correction (MSC). The 
MSC pathlength treatment was effective to compensate variations in sample 
thickness caused by particle size and scattering. Operation of MSC was 
performed both for the spectra of tablets and capsules content.  
Software 
The instrument was governed via a PC, using the RESULT Operation 
software from Thermo Electron Scientific Instruments Corporation both to 
acquire data and to construct the spectral library. Data pre-processing, 
analysis and results evaluation were performed using the TQ Analyst 
software, also supplied by Thermo Scientific.  
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Modelling 
We determined manufacturing variability by estimating the spectral 
differences between the batches of a certain sample with one of the 
supervised pattern recognition methods and various options of spectra 
grouping. As the discriminant analysis (DA) classification technique had 
been proven to determine the classes of known materials that are most 
similar to the tested sample, this technique was considered to be suitable for 
the solution of designed problem. For the numerical assessment of 
manufacturing variability the Mahalanobis distances measurement between 
batches was used. The research covered all the spectral range, so the number 
of original variables had to be reduced by the principal component analysis. 
In all cases the extraction of first 10 PCs provided a sufficient degree of 
cumulative explanation of 99.9% of the calibration set variables. Thus the 
obtained values of MD, calculated in the PC space, allowed ranking test 
classes and determining the threshold of quality differences between 
manufacturing batches. 
Spectral libraries and calibrations were formed separately for each 
sample drug. The first calibration set was constructed by the following 
principle: all spectra of every batch were included in one class, thus 
calibration set for every pharmaceutical contained the number of classes 
equal to the quantity of production batches. As the discriminant analysis was 
applied to the constructed data set it resulted into computation of pairwise 
distances between every class, measured in MD. This approach made it 
possible to reveal the highest spectral differences between separate lots in the 
recall of one type medicine. 
The second grouping was a kind of LOOCV: all spectra of a single 
batch were used as the validation data, while the remaining spectra of the rest 
series as the training data (library). This was repeated such that spectra of 
each batch were used once as the validation data. LOOCV access enabled to: 
1) evaluate the range of maximum spectral dispersion values in MD units; 2) 
set the value of quality threshold (MD), indicating the absence of reliable 
differences between the samples. 
Detailed results of Discriminant analysis, obtained using different 
approaches to grouping of original data are represented further. 
Batch-to-batch dispersion of capsules: pairwise distances between batches in 
simultaneous comparing 
In the course of discriminant analysis all recorded capsules’ spectra 
were included in the table of standards within TQ Analyst program: 144 
spectra for sample A1, 225 spectra for sample B1, 162 spectra for sample C1 
and 225 spectra for sample D1. Chemometric processing of NIR spectra 
allowed converting the spectral data and projecting it onto a subspace of 
smaller size, which was presented in the form of two-dimensional graphics in 
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Mahalanobis coordinates. For example, Figure 1 shows the result of 
discriminant analysis for sample A1 - pairwise distance graph between the 
separate batches of drug A1.  
 
 
Figure 1. Pairwise distances for sample A1: squares - batch 8, triangles - batch 16, 
circles - the rest of the series 
 
Each point of the resulting plane on Figure 1 corresponds to a 
particular spectrum of sample A1, at that triangles indicate the spectra of 
batch, selected by the vertical axis; squares denote the spectra of class 
selected on the horizontal axis. As can be seen from Figure 1, spectra of 
other batches, indicated as circles, fall in the resulting range between two 
axial classes. Gray lines, perpendicular to the axis, are the borderlines 
showing 95% confidence intervals for two selected classes. Points’ mixing in 
the central part of the plane characterizes NIR spectra similarity, and 
consequently similarity of manufacturing batches. In some cases reliable 
discrimination of production batches is almost impossible. At the same time, 
the graph shows that the spectra, corresponding to the axial series, form two 
distinct clusters of points at a maximum distance from each other. Changing 
the batches on X and Y-axis, we determined the maximum pairwise 
distances between spectra of all tested batches for sample A1. Obtained 
values are presented in Table 2. 
European Scientific Journal   September 2013  edition vol.9, No.27  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
18 
Table 2. Maximum spectral distances between individual batches of sample A1 
Batch 
number 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 8.79 10.87 13.38 8.17 12.47 12.73 11.04 11.75 9.98 11.04 13.76 13.76 13.76 13.95 12.31 
2  4.11 7.13 2.83 5.80 5.85 5.05 9.99 5.55 6.26 9.51 9.76 10.80 10.80 14.40 
3   4.94 3.97 4.41 4.68 4.53 10.69 5.18 5.82 7.33 7.93 11.11 9.74 15.98 
4    5.68 3.24 3.63 3.94 11.20 4.31 4.97 5.44 5.52 11.20 10.98 17.03 
5     5.29 5.44 4.34 9.44 3.37 4.78 7.94 8.29 9.98 9.94 13.46 
6      2.92 1.99 10.71 4.14 4.43 5.94 6.08 10.70 10.71 17.12 
7       3.01 11.43 4.91 5.59 6.79 6.85 11.43 11.36 17.21 
8        10.68 3.56 4.52 6.32 6.32 10.68 10.68 16.39 
9         8.91 7.93 12.95 12.41 3.73 3.68 10.62 
10          2.57 5.59 5.59 9.25 9.25 14.13 
11           6.49 6.25 7.96 7.96 13.82 
12            2.95 13.00 13.00 17.38 
13             12.26 12.35 17.01 
14              3.64 11.97 
15               11.80 
 
Table 2 indicates that the largest extension of spectral distance for sample A1 was detected between the series 12 and 
16 - 17.38 MD. None of these batches were considered an outlier, since the distance between the pair of them and all the 
other classes didn’t exceed the average meaning of dispersion in the table. 
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For discriminant analysis of other encapsulated samples, the same 
procedures were conducted: we converted the spectral data and projected it 
onto a subspace of smaller size, determined the largest extension of spectral 
distance between the batches and excluded the existence of outliers. The 
results are performed on Figure 2 (black color); batch-to-batch dispersion of 
different capsules turned to be in the range from 10.14 to 24.32, what 
exceeded the limit of 10-15 MD, mentioned in Mark & Tunnell work (1985). 
 
Figure 2. Maximum spectral distances between individual batches of capsules: black – 
NIR spectra and MSC, purple – NIR spectra first derivative and MSC 
 
The obtained meanings were considered rather high and potentially 
risky as they could lead to false-negative results in the drug identification. 
When we measured capsules content, emptied from the coatings, the 
influence of variations in sample’s thickness, size, shape, orientation 
between different batches was greater than in tablet’s case. Tablets were 
more homogeneous samples, as their characteristics, such as size, thickness, 
surface type, uniformity of content were certified by manufacturer. In order 
to minimize physical differences in capsule samples, fist-derivative pre-
processing with Savitsky-Golay filter (7 points, polynomial order 3) was 
additionally applied to the spectra of capsules. As a result of this procedure, 
the values of batch-to-batch dispersion decreased (Figure 2, purple color) 
and fitted to the indicated in research of Mark & Tunnell (1985) threshold of 
10-15 MD.  
Batch-to-batch dispersion of tablets: pairwise distances between drug 
batches in simultaneous comparing 
The procedure of DA calibration for tablet samples was just the same 
as for capsules. But the amount of test drugs was higher, there were several 
samples from one manufacturer, medicines containing the same API with 
different dose, single-component and combined preparations (see Table 1). 
Figure 3 displays the results of discriminant analysis for the tablet calibration 
set, where each batch of a drug was considered as a separate class. 
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Figure 3. Maximum spectral distances between individual batches of tablets 
 
Performed MD computations allowed the determination of maximum 
spectral distance between separate batches; these values were represented in 
the graph (Fig.3). Different colors indicated drugs of one manufacturer 
(samples with letters C, G, J). Integrally the range of spectral distances 
between the individual batches appeared from 3.08 (sample F1) to 11.28 
(sample J3), that correlated with the results reported by Mark & Tunnell 
(1985). The value of spectral dispersion for most of the samples did not 
exceed 10 MD, except the sample J3. We supposed the reason was in the 
difficulties, met during the process of biological raw material 
standardization. Sample J3 is a high-purity deproteinized calf blood 
derivative, obtained by dialysis and ultrafiltration. The drug contains a set of 
micro-and macronutrients, amino acids, oligopeptides, nucleosides, fatty 
acids, oligosaccharides, which could vary resulting from deviations in 
quantitative composition of raw calf blood. 
It seemed interesting to evaluate the batch-to-batch dispersion of 
pharmaceuticals, made by one producer and containing the same active 
ingredient but in different doses. This was achieved in course of discriminant 
analysis of spectral data, provided by samples C3, C4 and J1, J2. Analysis 
showed that in whole batch-to-batch variability in all mentioned samples (C3 
and C4, J1 and J2) was close in value – nearly 6 MD (Fig.3). Although it 
became evident, that pharmaceuticals with lower doses had tendency to 
higher values of dispersion. Table 3 provided some data about samples, 
containing carvedilol and lornoxicam. 
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Table 3. API concentration and batch-to-batch dispersion (MD) for the samples C3, 
C4, J1, J2 
API carvedilol lornoxicam 
Encoded sample name C3 C4 J1 J2 
API dose, mg 12.5 25 4 8 
Tablet average weight, mg 180 180 215 211 
API concentration, % 6.94 13.9 1.86 3.79 
Batch-to-batch dispersion, 
MD 7.65 5.46 5.54 4.80 
 
One can notice that with the increasing of API doses the tablet weight 
remained practically constant. That leaded to the growth of API 
concentration in tablet. Therefore, fluctuations of API distribution among 
excipients in the tablet with smaller dose could be the reason for the larger 
manufacturing variability of the former. 
While completing the resulting tables with the meanings of maximal 
pairwise distances between the batches of tableted samples, we faced one 
observation that was more interesting. Discriminant analysis of tablets G1, 
G2, I1, and K1 allowed getting some latent information, characterizing 
batch-to-batch and in-batch dispersion of sample's spectra in the two-
dimensional plane of principal components space. As shown in Figure 4 
spectra of sample G1 were arranged in groups of three. 
 
Figure 4. Results of discriminant analysis for the sample G1: comparison of batch-to-
batch and in-batch dispersion 
 
Each group of three points indicated the NIR spectra of sample G1, 
recorded for a single tablet from production batch. Figure 4 demonstrated 
that the difference between spectra in a single class was higher than 
dispersion between classes, some of which even overlapped with each other 
(batch 3 and 5). The same findings, when in-batch spectra dispersion 
exceeded the batch-to-batch dispersion, were also obtained for samples G2, 
I1, and K1. We considered these results were due to such technological 
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features of tablets manufacturing process as the mixing quality and 
flowability parameters of granulated material. Thus, while the drug 
technology from batch-to-batch was reproduced at a high level, the quality 
indexes of individual tablets within the same batch varied greatly, but stayed 
within normative demands. 
To summarize all of the above, the general parameters of batch-to-
batch dispersion despite some differences were comparable with each other 
for all of the investigated drugs. The absence of reliable qualitative 
differences between the series of tested drugs proved the high level of quality 
and reproducibility of tested products. The value of spectral dispersion 
between the batches of the samples did not exceed 10 MD, except the 
encapsulated samples and tablets with blood derivative, what correlated with 
the values met in literature [19]. The obtained results of spectral range 
magnitude between batches (MD) were thought the unique characteristics of 
each product. This measure specified the batch-to-batch reproducibility for 
the drug - the smaller distance between the spectral classes (series), the 
homogeneous product. In prospect these established in discriminant analysis 
numeric indexes of spectral dispersion could be used as an additional quality 
indicators. The latter could be incorporated into industry standards and 
regulations, where the manufacturer, depending on the possibility to 
reproduce productive conditions, would set the optimal value of the 
permissible batch-to-batch dispersion. This will allow avoiding the labor-
consuming operations for the construction and constant updating of spectral 
library with a large sampling. 
Leave-one-out-cross-validation (LOOCV) results: the range of maximum 
spectral dispersion and the meanings of quality thresholds (MD) 
In the practice of pharmaceutical analysis, NIR spectroscopy is often 
used to confirm the authenticity of the drug. Herewith it is necessary to 
compare the spectra of under tested drug with a library of standards spectra 
and draw a conclusion about the sample quality. As it was mentioned before 
discriminant analysis together with Mahalanobis distance is suitable for that. 
The only difficulty is that proper control limits (MD), under which the 
sample meets qualification criterion, must be pre-set. So that was the purpose 
of our second type calibration set construction – LOOCV, which provided 
more stable MD results, almost uniform for all the tested drugs. The new 
values of dispersion were considerably less than the values, obtained by 
simultaneous comparison of separate product batches (Fig. 2, 3). 
Mathematical features of discriminant analysis can explain this: during the 
calibration, software calculated the average spectrum for each comparison 
class and created a model of distribution by measuring the deviations at each 
frequency range. The averaged spectrum was then subtracted from each 
spectrum providing the range of dispersion. For this reason, the association 
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of all batches' spectra in one common class significantly changed the 
averaged spectrum, and consequently the results of final comparison between 
tested drug and spectral library. 
During the process of calibration, the result tables with the meanings 
of pairwise distances were constructed for all the samples. They included the 
information about the maximum value of dispersion in MD between every 
batch and the library class. The minimum and maximum values for each 
sample were extracted from these result tables to obtain the range of peak 
dispersion (Fig. 5). 
 
Figure 5. LOOCV results: the range of maximum spectral dispersion values (MD) 
 
Thereby, in such a comparison for the majority of the being tested 
drugs (77.3 %) the magnitude of spectral differences fitted into 3 MD (Fig. 
6). For the 18.2 % of the investigated drugs the range of peak dispersion did 
not uphold 4 MD, and for the 4.5 % - was more than 4 MD (Fig. 6). 
 
Figure 6. Distribution diagram: investigated drugs in accordance with different ranges of 
maximum spectral distance between batches 
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Therefore, the method enabled to determine the proper control limits 
on the MD, under which the sample meets qualification criterion. The results 
were largely coincided with the theoretical – 3 MD (Mark, 2001, p. 321) and 
experimental data – 4 MD (Ritchie et al., 2003). 
Conclusion 
The results of the investigation displayed the use of discriminant 
analysis together with the MD is an accurate mean for the determination of 
batch-to-batch drug dispersion. The value of spectral dispersion for the most 
of samples in the research did not exceed 10 MD, except the encapsulated 
samples and tablets with blood derivative, what correlated with the values 
met in literature (Mark & Tunnell, 1985). For the medicines authentication 
we recommended the introduction of an additional indicator of spectral 
variation, which was determined empirically in the result of LOOCV. 
Evaluated so Mahalanobis distance threshold, indicating the absence of 
reliable differences in qualitative characteristics, proved to be equal 3 for the 
majority of drugs, what was in a good agreement with the theoretically 
determined limit (Mark, 2001, p. 321).  
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